[123I] N-（2-二乙氨基乙基）-4-碘苯甲酰胺在原发性和转移性眼黑色素瘤诊断中的临床研究
Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma.
作者信息
Bacin F, Michelot J, Bonafous J, Veyre A, Moreau M F, Kemeny J L, Chossat F, Bekhechi D
机构信息
CHU Gabriel Montpied, Service d'Ophtalmologie, Clermont-Ferrand, France.
出版信息
Acta Ophthalmol Scand. 1998 Feb;76(1):56-61. doi: 10.1034/j.1600-0420.1998.760110.x.
PURPOSE
To assess the value of scintigraphy with [123I]N-(2-diethylaminoethyl)-4-iodobenzamide (BZA), a phase II clinical trial was performed on 48 patients with a suspicion of ocular melanoma.
METHODS
56 examinations were performed to image lesions with a clinical diagnosis of primary ocular melanoma before and/or after treatment, to observe the results in simulating lesions or to image metastases.
RESULTS
Ocular BZA-scintigraphy demonstrated a sensitivity of 86%, and a specificity of 83%. Whole-body scintigraphy was used in the follow-up of treated patients and could be repeated. We imaged orbital recurrence, known and occult metastases, specially in the liver. After 9 conservative treatments ocular BZA-scintigraphy was negative in 9 eyes.
CONCLUSION
The BZA-scintigraphy in combination with other diagnostic procedures appeared to be a suitable method in the diagnosis of ocular melanoma and a potentially useful imaging modality to screen for ocular malignant melanoma metastases.
目的
为评估[123I]N-(2-二乙氨基乙基)-4-碘苯甲酰胺（BZA）闪烁扫描术的价值，对48例疑似眼黑色素瘤患者进行了一项II期临床试验。
方法
进行了56次检查，以对治疗前和/或治疗后的原发性眼黑色素瘤临床诊断病变进行成像，观察模拟病变的结果或对转移灶进行成像。
结果
眼部BZA闪烁扫描术的敏感性为86%，特异性为83%。全身闪烁扫描术用于治疗后患者的随访，且可重复进行。我们对眼眶复发、已知和隐匿性转移灶进行了成像，特别是在肝脏。9次保守治疗后，9只眼的眼部BZA闪烁扫描术结果为阴性。
结论
BZA闪烁扫描术与其他诊断程序相结合似乎是诊断眼黑色素瘤的一种合适方法，也是筛查眼恶性黑色素瘤转移灶的一种潜在有用的成像方式。
Zotero 插件